Drug profile · INN
lamivudine
3TC
lamivudine (3TC) is a dna inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lamivudine
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 21
- Data quality
- 0.89
Quick answer
lamivudine (3TC) is a dna inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lamivudine?
lamivudine (3TC) is a dna inhibitor. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lamivudine?
3TC is a marketed brand name for lamivudine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lamivudine?
lamivudine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.